{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T07:05:36Z","timestamp":1785222336008,"version":"3.55.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":1260,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Hyperkalaemia (HK) is common in heart failure (HF) patients, related to renal dysfunction and medical treatment. It limits medical therapy optimization, which impacts prognosis. New potassium (K) binders help control HK, allowing better medical management of HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A retrospective multicentre register included all outpatients with HF and HK (K \u2265 5.1 mEq\/L) treated with patiromer according to current recommendations. We evaluated analytic and clinical parameters before starting the treatment and at 7, 30 and 90 days, as well as adverse events related to patiromer and treatment optimization. We included 74 patients (71.6% male) with a mean age of 70.8 years (SD 9.2). Sixty-seven patients (90.5%) presented HK in the previous year. Forty patients (54.1%) underwent down-titration of a renin\u2013angiotensin\u2013aldosterone inhibitor (RAASi) or a mineralocorticoid receptor antagonist (MRA), and 27 (36.5%) stopped any of them due to HK. Initial K was 5.5 mEq\/L (SD 0.6), with a significantly reduction at 7 days (4.9 mEq\/L (SD 0.8); P &amp;lt; 0.001), maintained at 90 days (4.9 mEq\/L (SD 0.8); P &amp;lt; 0.001). There were no other electrolyte disturbances, with a slight improvement in renal function [glomerular filtration rate 39.6 mL\/min (SD 20.4) to 42.7 mL\/min (SD 23.2); P = 0.005]. Adverse events were reported in 33.9% of patients, the most common being hypomagnesaemia (16.3%), gastrointestinal disturbances (14.9%) and HK (2.8%). Withdrawal of patiromer was uncommon (12.2%) due to gastrointestinal disturbances in 66.7% of cases.<\/jats:p>\n                    <jats:p>Nine patients (12.2%) started on a RAASi, and 15 patients (20.3%) on an MRA during the follow-up. Forty-five patients (60.8%) increased the dose of RAASi or MRA, increasing to target doses in 5.4 and 10.8% of patients, respectively. At 90 days, NTproBNP values were reduced from 2509.5 pg\/mL [IQR 1311\u20134,249] to 1396.0 pg\/mL [IQR 804\u20134263]; P = 0.003, but the reduction was only observed in those who optimized HF medical treatment [NTproBNP from 1950.5 pg\/mL (IQR 1208\u20133403) to 1349.0 pg\/mL (IQR 804\u20132609); P &amp;lt; 0.01]. NYHA functional class only improved in 7.5% of patients, corresponding with those who optimized HF medical treatment. Compared with the previous 3 months before patiromer treatment, the rate of hospitalization was reduced from 28.4 to 10.9% (P &amp;lt; 0.01), and the emergency room visits from 18.9 to 5.4% (P &amp;lt; 0.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a real-life cohort of patients with HF, patiromer reduced and maintained K levels during 3 months of follow-up. The most common adverse events were hypomagnesaemia and gastrointestinal disturbances. Patiromer helps optimize medical treatment, increasing the percentage of patients treated with RAASi and MRA at target doses. At the end of follow-up, natriuretic peptides values and hospital visits were reduced, suggesting the benefit of optimizing HF medical treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13976","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T03:45:19Z","timestamp":1656042319000},"page":"3071-3078","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Experience with the Potassium Binder Patiromer in Hyperkalaemia Management in Heart Failure Patients in Real Life"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3839-7336","authenticated-orcid":false,"given":"Alberto","family":"Esteban-Fern\u00e1ndez","sequence":"first","affiliation":[{"name":"Faculty of Health Sciences, Universidad Alfonso X el Sabio (UAX) , Villanueva de la Ca\u00f1ada ,","place":["Spain"]},{"name":"Cardiology Service, Hospital Universitario Severo Ochoa , Legan\u00e9s ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Ortiz Cort\u00e9s","sequence":"additional","affiliation":[{"name":"Cardiology Service, Hospital San Pedro de Alc\u00e1ntara , C\u00e1ceres ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"L\u00f3pez-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Heart Failure Unit, Cardiology Service, Hospital Universitario Virgen de las Nieves , Granada ,","place":["Spain"]},{"name":"IDIBELL, Instituto de Investigaci\u00f3n Biosanitaria ibs , Granada ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Recio Mayoral","sequence":"additional","affiliation":[{"name":"Cardiology Service, Hospital Universitario Virgen Macarena , Sevilla ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Camacho Jurado","sequence":"additional","affiliation":[{"name":"Cardiology Service, Hospital Universitario de Puerto Real , C\u00e1diz ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"G\u00f3mez Otero","sequence":"additional","affiliation":[{"name":"Cardiology Service, Hospital Universitario de Santiago , A Coru\u00f1a ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Molina","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Universidad Alfonso X el Sabio (UAX) , Villanueva de la Ca\u00f1ada ,","place":["Spain"]},{"name":"Cardiology Service, Hospital Universitario Severo Ochoa , Legan\u00e9s ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Almenar Bonet","sequence":"additional","affiliation":[{"name":"Heart Failure and Transplant Unit, Cardiology Service, Hospital Universitari i Polit\u00e8cnic La Fe , Valencia ,","place":["Spain"]},{"name":"CIBERCV , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"L\u00f3pez-Vilella","sequence":"additional","affiliation":[{"name":"Heart Failure and Transplant Unit, Cardiology Service, Hospital Universitari i Polit\u00e8cnic La Fe , Valencia ,","place":["Spain"]},{"name":"CIBERCV , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"key":"2026012114155533700_ehf213976-bib-0001","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","article-title":"2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction: A report of the American College of Cardiology Solution Set Oversig","volume":"77","author":"Writing Committee","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026012114155533700_ehf213976-bib-0002","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114155533700_ehf213976-bib-0003","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC heart failure long-term registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026012114155533700_ehf213976-bib-0004","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on the efficacy of spironolactone in patients with severe heart failure: Insights from RALES (randomized Aldactone evaluation study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026012114155533700_ehf213976-bib-0005","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: A prospective European study","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012114155533700_ehf213976-bib-0006","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/ejhf.900","article-title":"Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: Findings from BIOSTAT-CHF","volume":"19","author":"Ferreira","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012114155533700_ehf213976-bib-0007","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/FJC.0000000000000641","article-title":"Sacubitril\/valsartan in daily clinical practice: Data from a prospective registry","volume":"73","author":"Vicent","year":"2019","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026012114155533700_ehf213976-bib-0008","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/CIRCULATIONAHA.117.030576","article-title":"Long-term potassium monitoring and dynamics in heart failure and risk of mortality","volume":"137","author":"N\u00fa\u00f1ez","year":"2018","journal-title":"Circulation"},{"key":"2026012114155533700_ehf213976-bib-0009","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.recesp.2019.05.004","article-title":"Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA heart failure long-term registry","volume":"73","author":"Crespo-Leiro","year":"2020","journal-title":"Rev Espa\u00f1ola Cardiol (English Ed)"},{"key":"2026012114155533700_ehf213976-bib-0010","first-page":"211","article-title":"Prognostic implications of hypo and hyperkalaemia in acute heart failure with reduced ejection fraction. Analysis of cardiovascular mortality and hospital readmissions","volume":"158","author":"del Pilar Laymito-Quispe","year":"2022","journal-title":"Med Clin (Barc)"},{"key":"2026012114155533700_ehf213976-bib-0011","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ehjcvp\/pvy015","article-title":"Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: Coordinated by the working group on cardiovascular pharmacotherapy of the European Society of Cardiology","volume":"4","author":"Rosano","year":"2018","journal-title":"Eur Hear J Cardiovasc Pharmacother"},{"key":"2026012114155533700_ehf213976-bib-0012","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ejhf.1531","article-title":"Clinical practice update on heart failure 2019: Pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the heart failure Association of the European Society of cardiology","volume":"21","author":"Seferovic","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012114155533700_ehf213976-bib-0013","first-page":"235","article-title":"Consensus on the management of hyperkalemia in patients with heart failure: Recommendations from the SEC-SEMI","volume":"222","author":"Almenar Bonet","year":"2022","journal-title":"Rev Cl\u00ednica Espa\u00f1ola (English Ed)"},{"key":"2026012114155533700_ehf213976-bib-0014","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/1074248416629549","article-title":"Mechanism of action and pharmacology of Patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia","volume":"21","author":"Li","year":"2016","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2026012114155533700_ehf213976-bib-0015","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/ejhf.1860","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): Results in the pre-specified subgroup with heart failure","volume":"22","author":"Rossignol","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114155533700_ehf213976-bib-0016","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur Heart J"},{"key":"2026012114155533700_ehf213976-bib-0017","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease the AMETHYST-DN randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA - J Am Med Assoc"},{"key":"2026012114155533700_ehf213976-bib-0018","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): A phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"key":"2026012114155533700_ehf213976-bib-0019","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"key":"2026012114155533700_ehf213976-bib-0020","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.echo.2010.05.010","article-title":"Guidelines for the echocardiographic assessment of the right heart in adults: A report from the American Society of Echocardiography","volume":"23","author":"Rudski","year":"2010","journal-title":"J Am Soc Echocardiogr"},{"key":"2026012114155533700_ehf213976-bib-0021","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/SMJ.0b013e31819e8978","article-title":"Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol","volume":"102","author":"McGowan","year":"2009","journal-title":"South Med J"},{"key":"2026012114155533700_ehf213976-bib-0022","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1681\/ASN.2010010079","article-title":"Ion-exchange resins for the treatment of hyperkalemia: Are they safe and effective?","volume":"21","author":"Sterns","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2026012114155533700_ehf213976-bib-0023","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/14740338.2018.1462335","article-title":"The tolerability and safety profile of patiromer: A novel polymer-based potassium binder for the treatment of hyperkalemia","volume":"17","author":"Pitt","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"2026012114155533700_ehf213976-bib-0024","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ehf2.12265","article-title":"Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease","volume":"5","author":"Pitt","year":"2018","journal-title":"ESC Hear Fail"},{"key":"2026012114155533700_ehf213976-bib-0025","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40801-021-00254-7","article-title":"Safety and tolerability of the potassium binder patiromer from a global pharmacovigilance database collected over 4 years compared with data from the clinical trial program","volume":"8","author":"Rossignol","year":"2021","journal-title":"Drugs - Real World Outcomes"},{"key":"2026012114155533700_ehf213976-bib-0026","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.rccl.2021.06.005","article-title":"Fisiopatolog\u00eda, diagn\u00f3stico y tratamiento de la hipomagnesemia en pacientes con insuficiencia cardiaca","volume":"56","author":"Esteban-Fern\u00e1ndez","year":"2021","journal-title":"REC CardioClinics"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13976","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13976","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/5\/3071\/65352077\/eschf_9_5_3071.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/5\/3071\/65352077\/eschf_9_5_3071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:19:04Z","timestamp":1769023144000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/9\/5\/3071\/8323047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,6,24]]},"published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13976","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10]]},"published":{"date-parts":[[2022,6,24]]},"assertion":[{"value":"2021-10-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}